Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential

Lung malignant tumors are a type of cancer with high incidence and mortality rates worldwide. Non-small cell lung cancer (NSCLC) accounts for over 80% of all lung malignant tumors, and most patients are diagnosed at advanced stages, leading to poor prognosis. Over the past decades, various oncogenic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer gene therapy 2024-07, Vol.31 (7), p.961-969
Hauptverfasser:	Tang, Yining, Pu, Xi, Yuan, Xiao, Pang, Zhonghao, Li, Feng, Wang, Xu
Format:	Artikel
Sprache:	eng
Schlagworte:	631/337 631/67/1059/602 Animals Biomedical and Life Sciences Biomedicine Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Drug delivery Drug development Drug resistance Gene Expression Gene Therapy Humans Immune checkpoint inhibitors Immunosuppressive agents K-Ras protein Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Molecular modelling Molecular Targeted Therapy - methods Mutation Non-small cell lung carcinoma Oncogenes Patients Prognosis Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors Proto-Oncogene Proteins p21(ras) - genetics Review Article Sarcoma Small cell lung carcinoma Therapeutic targets Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!